Revolutionizing Scoliosis Treatment: Dr. Zeke Harkleroad Achieves Remarkable Results Through Groundbreaking Technology
December 19, 2023 10:00 ET
|
Bee Caves Scoliosis and Chiropractic
AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Dr. Zeke Harkleroad, a leading authority in spinal health and wellness, is proud to announce the launch of a revolutionary technology that has been...
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
December 18, 2023 06:30 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
December 15, 2023 09:05 ET
|
Biogen Inc.
Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of...
Muscular Dystrophy Association Launches Holiday Retail Campaign in Thousands of Retail Locations Nationwide
November 01, 2023 09:00 ET
|
Muscular Dystrophy Association
New York, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today launched its largest Holiday Retail Campaign to fundraise in thousands of retail locations nationwide from...
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
October 30, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Muscular Dystrophy Association-Supported Drug AGAMREE® (vamorolone) Approved for the Treatment of Duchenne Muscular Dystrophy by the FDA
October 26, 2023 16:24 ET
|
Muscular Dystrophy Association
New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique...
Muscular Dystrophy Association Celebrates FDA Approval of ZILBRYSQ® zilucoplan for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients
October 18, 2023 14:36 ET
|
Muscular Dystrophy Association
New York, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of...
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
August 16, 2023 10:56 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Muscular Dystrophy Association Celebrates FDA Approval of UCB’s RYSTIGGO for the Treatment of Generalized Myasthenia Gravis
June 27, 2023 17:18 ET
|
Muscular Dystrophy Association
New York, June 27, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of RYSTIGGO (rozanolixizumab-noli) for the...
Muscular Dystrophy Association Celebrates FDA Approval of argenx’s Vyvgart Hytrulo Injection for Treatment of Generalized Myasthenia Gravis
June 20, 2023 21:29 ET
|
Muscular Dystrophy Association
New York, June 20, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of subcutaneous (SC) Vyvgart Hytrulo (efgartigimod...